Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alphamab Oncology of Suzhou Closes $100 Million A Round for Cancer Drugs

publication date: Nov 19, 2018

Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms, including bispecific, protein engineering and antibody screening technologies. Stressing its novel immunocology candidates, Alphamab Oncology is focused on developing multi-functional cancer biologics, aiming at next-gen or best-in-class medicines that address global needs. The company has four candidates in clinical trials in the US, China, Japan and Australia. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital